Henlius
Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Henlius, founded in February, 2010 and headquartered in Shanghai, is a medical company involved in tumors and autoimmune diseases. The founder is Chen Qiyu. Listed on the HKEX on September 25, 2019, the company's major shareholders are Shanghai Fosun New Medicine Research Co., Ltd., Henlius Biopharmaceuticals Inc. and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. Rivals that have direct and indirect competition with Henlius include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing
EqualOcean has learned that DP Technology(深势科技), an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital(众源资本), MSA Capital(和玉资本), Loyal Valley Capital(正心谷资本), Evergreen Scitech Delta(深势科技), and many other industry-specific investors, with Lighthouse Capital(光源资本) serving as the exclusive financial advisor.
Aug 22, 2023 03:34 PM